Comparative bioavailability of two formulations of terbinafine: Data from a cross-over, randomised, open-label bioequivalence study in healthy volunteers

Arzneimittel-Forschung/Drug Research

Volumn 54, Issue 11, 2004, Pages 757-762

  Almeida, Susana ^a   Filipe, Augusto ^a   Vallée, François ^b   Tanguay, Mario ^b   Larouche, Richard ^b   Lainesse, Audrey ^b  

^a Tecnimede Group   (Portugal)

^b Anapharm Canada   (Canada)

Author keywords

Antifungal agent; CAS 78628 80 5; Terbinafine, bioavailability, bioequivalence, clinical pharmacokinetics, gender

Indexed keywords

TERBINAFINE;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CALCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG FORMULATION; FEMALE; GENDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NON COMPARTMENTAL ANALYSIS; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TABLET; TANDEM MASS SPECTROMETRY;

EID: 9944248774     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1297033     Document Type: Article

References (6)

1. Jain, S., Sehgal, V. N., Terbinafine, a unique oral antifungal: current perceptions. Int. J. Dermatol. 39, 412 (2000)
2. McClellan, K. J., Wiseman, L. R., Markham, A., Terbinafine: an update of its use in superficial mycoses. Drugs 58, 179 (1999)
3. CPMP (Committee for Proprietary Medicinal Products): Note For Guidance on the Investigation of Bioavailability and Bioequivalence (2001)
4. Chen, M. L., Lee, S. C., Ng, M. J. et al., Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin. Pharmacol. Ther. 68, 510 (2000)
5. Good Clinical Practice Consolidated Guideline. International Conference on Harmonisation. E6 (1996)
6. Koytchev, R., Erenmemisoglu, A., van der Meer, M. J. et al., Clinical relevance of bioequivalence acceptance criteria: the example of terbinafine. Arzneim.-Forsch./Drug Res. 53, 289 (2003)